

PTAC Decisions 2006-2004 - New Products (first 10 positive/negative decisions)

Meeting Dat	Product name	Generic name	NCE	Decision	Reason	Priority	Criteria cited	Nii	One	Two	Three	Four	Five	Six	Seven	Eight
Nov-06	Faslodex	fulvestrant	Yes	Yes	place in therapy unclear, reco 3rd-line therapy	Low	i,iii,vi		1		1			1		
Nov-06	Macrogol	movicol	Yes	Yes	Special Authority access	Medium	i,iii,iv		1		1	1				
Nov-06	Traclear	bosentan	Yes-reapplication	Yes	reaffirmed previous (Feb 05)reco to list with low priority	Low		1								
Aug-06	Viread	tenofovir	Yes	Yes	new evidence persuasive	Moderate-High	i,iii,iv		1		1	1				
Aug-06	Exjade	deferasirox	Yes	Yes	major compliance & patient tolerability benefit	High	i,iii,iv		1		1	1				
May-06	Micardis	telmisartan	Yes	Yes	longer 1/2 life than comparators Subject to being cost neutral		iv,vi					1		1		
Feb-06	Arimidex	anastrozole	Yes-reapplication	Yes	accepted new evidence	Moderate	i,iii,iv,vi,vii,viii		1		1	1		1		1
Nov-05	Temodal	temozolomide	Yes	Yes*	accepted clinical evidence of significant benefit	High	i,iii,vii,viii		1		1				1	1
Aug-05	Keppra	levetiracetam	Yes	Yes*	no explicit reason	High	i,iii,iv		1		1	1				
Feb-05	Viread	tenofovir	Yes	Yes*	no explicit reason	Moderate	iii				1					
Nov-06	Baraclude	entecavir	Yes	No	place in therapy not clear		i,iii,iv		1		1	1				
Nov-06	Caelyx	doxorubicin	Yes	No	high cost/unfavourable toxicity profile		i,iii,iv		1		1	1				
Aug-06	Alimta	pemetrexed disodium	Yes	No	Inadequate efficacy/clinical need met		i,iii,iv		1		1	1				
Aug-06	Certican	everolimus	Yes	No	place in therapy unclear		i,iii,iv		1		1	1				
May-06	Tarceva	erlotinib	Yes	No	relatively high cost/unacceptable rate & severityof side effects		i,iii,iv,viii		1		1	1				1
May-06	Fabrazyme	agalsidase beta	Yes	No	High cost/issue for PHARMAC			1								
May-06	Visudyne	verteporfin	Yes- reapplication	No	PS inappropriate funding mechanism			1								
May-05	Emtriva	emtricitabine	Yes	No	adequate alternative treatments available		iv					1				
Aug-04	Exiba	memanthine	Yes	No	place in therapy unclear			1								
Feb-04	Crestor	rosuvastatin	Yes	No	adequate alternative treatments available			1								
								5	12	0	13	12	0	3	2	3

